Uyaina Arshad Hos Malaysia Pertama Kendali Rancangan Di Indonesia

Rezeki yang tidak putus-putus buat pengcara Uyaina Arshad. Manakan tidak, selepas menjadi juara Puteri Muslimah Asia, nampaknya Uyaina telah ‘disunting’ mengendalikan sebuah program di Indonesia. Is Now a Good Time to Play the Biotech Sector With TransEnterix? Partner Content By Tipranks | July 13, 2018 — 2:51 AM EDT SHARE ADD TO WATCHLIST TRXC TransEnterix Inc 4.44 0.00% View Watchlist TransEnterix Inc (NYSE: TRXC), a robotic medical device company aiming to digitize the interface between surgeons and patients in laparoscopy, surged an impressive 125.9% in the first half of 2018, owing to a multitude of bullish factors. The company seeks to assist qualified laparoscopists to perform complex surgeries with the assistance of robotic technology. Here we use TipRanks data to take a closer look at what Wall Street's top analysts see in store for this volatile stock. The company, which was included in the Russell 2000 index just last month, reported an impressive increase in top-line numbers. “We are excited to be joining the Russell 2000 Index, which puts us alongside many of the largest public companies in the U.S.,” said CEO Todd M. Pope. “We have worked diligently to create value for our shareholders, and we believe our inclusion represents a great opportunity to continue to do so by increasing our visibility and exposure to investors,” he added. From a fundamentals perspective, TransEnterix stated in a preliminary unaudited report for Q2 2018 that its revenue numbers fall in the $6-$6.3 million range in the quarter, compared with merely $1.5 million in the year ago quarter and $4.8 million in the previous quarter. Moreover, the company stated that it had $98 million in cash and cash equivalents at the end of June. The primary factor driving the stock higher was increased sale of the company’s flagship Senhance surgical robotic system, for which it received FDA clearance in October last year. TransEnterix recently also got a lift in May when it announced the FDA cleared the use of Senhance system in two more procedures, namely cholecystectomy (gallbladder removal) and inguinal hernia repair, doubling the total addressable market from 1.5 million to 3 million. “Importantly, this indication expansion represents another important regulatory milestone for TransEnterix, as it continues to successfully navigate FDA. And, with a now broader set of surgical indications, we believe TransEnterix is better positioned today to engage both surgeons and hospital administrations in robotic acquisition discussions,” said Stifel Nicolaus analyst Rick Wise, who currently has a $5.5 price target for TransEnterix (27% upside potential). The company sold two Senhance systems in the first quarter of 2018 and the management reported the sale of 4 systems in the preliminary report for Q2 2018. “We had a strong second quarter as we continued to drive sales of Senhance globally while at the same time making significant progress towards our 2018 goals, including the expansion of Senhance’s indications for use and portfolio of instruments,” Todd M. Pope said. He added, “We look forward to continuing to build upon the momentum we developed during the first half of the year to drive the widespread adoption of Senhance.” Per the TipRanks analyst consensus, the stock currently floats a cautiously optimistic Moderate Buy rating. Out of the four analysts surveyed in the past 3 months, 2 have a buy rating while 2 have a hold rating on the stock. Moreover, the price target on the stock is currently $4.5, with the high estimate reaching $5.5 and low estimate being $3.5, indicating a 5.4% upside from current levels. All in all, TransEnterix presents a good investment opportunity, considering its impressive fundamentals and demand for robotics in health-tech. At a time when the healthcare industry faces skyrocketing costs and a shortage of qualified workers, robotics in the healthcare sector presents a massive opportunity. Read more: Is Now a Good Time to Play the Biotech Sector With TransEnterix? | Investopedia https://www.investopedia.com/investing/now-good-time-play-biotech-sector-transenterix/#ixzz5L7WLmHb4 Follow us: Investopedia on Facebook

Share this post